Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Rhea-AI Summary
Innocan Pharma (OTCQB: INNPF, CSE: INNO) announced it now anticipates listing its common shares on NYSE American on or around January 30, 2026, subject to approval of its listing application and continued compliance with exchange rules. The company is conducting a concurrent offering of securities, subject to market conditions and regulatory approval, with additional details to be filed with the SEC and SEDAR+. Innocan expects OTCQB trading to continue until the close on or about January 29, 2026, after which OTCQB trading will terminate upon effectiveness of the NYSE American listing. No shareholder action is required prior to the listing.
Positive
- Anticipated NYSE American listing on or around Jan 30, 2026
- Concurrent securities offering planned (capital-raising potential)
- Common shares to remain listed on CSE under symbol INNO
Negative
- Listing is subject to NYSE approval and continued compliance
- Concurrent offering is subject to market conditions and regulatory approval
- OTCQB trading expected to terminate on or about Jan 29, 2026
News Market Reaction
On the day this news was published, INNPF declined 8.74%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HERZLIYA,
In connection with the anticipated NYSE listing, Innocan is also conducting a concurrent offering of its securities, subject to market conditions and regulatory approval (the "Offering"). Additional details regarding the Offering will be provided through the Company's filings with the Securities and Exchange Commission ("SEC") and SEDAR+.
Innocan expects that its common shares will continue to trade on the OTC Markets' OTCQB until the close of the market on or about January 29, 2026. Upon effectiveness of the listing on the NYSE American, trading of the common shares on the OTCQB will terminate. Stockholders of Innocan do not need to take any action prior to the listing of Innocan's shares on the NYSE American. Innocan's common shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol "INNO".
This communication does not constitute an offer, or a solicitation of an offer, to buy or sell any securities, investment or other specific product, or a solicitation of any vote or approval, nor shall there be any sale of securities, investment or other specific product in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Innocan Pharma Corporation
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its
www.innocanpharma.com
For further information, please contact:
Iris Bincovich, CEO
15162104025+
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary Note Regarding Forward-Looking Statements
Certain information set forth in this news release, including, without limitation, information regarding the anticipated listing on the NYSE American and the Offering, research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated listing and the Offering, benefits of Innocan'sproducts, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.
Logo - https://mma.prnewswire.com/media/2570689/5665461/Innocan_Pharma_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/innocan-pharma-corporation-anticipates-listing-on-the-nyse-american-stock-exchange-with-concurrent-offering-302671702.html
SOURCE Innocan Pharma Corporation
FAQ
When does Innocan (INNPF) expect to list on NYSE American?
Will Innocan (INNPF) continue trading on the OTCQB after the NYSE listing?
Is Innocan (INNPF) raising capital alongside the NYSE listing?
Do Innocan shareholders need to take action before the NYSE listing?
Where will Innocan shares trade after the NYSE listing besides NYSE American?
